Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DAF-16/FOXO and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways are interconnected regulatory networks that govern cellular responses to stress, metabolism, and longevity. DAF-16 is the Caenorhabditis elegans ortholog of the human Forkhead box O (FOXO) family of transcription factors, which includes FOXO1, FOXO3, FOXO4, and FOXO6 [1, 2]. These transcription factors regulate genes involved in antioxidant defense (e.g., SOD2, catalase), DNA repair, and apoptosis [3]. The p38 MAPK pathway is a stress-activated protein kinase cascade that responds to stimuli such as oxidative stress, UV radiation, and inflammatory cytokines [4]. In many contexts, p38 MAPK phosphorylates FOXO proteins, influencing their nuclear localization and transcriptional activity, thereby integrating environmental signals into the cellular survival program [5, 6]. Dysregulation of these pathways is implicated in aging, cancer, neurodegeneration, and chronic inflammatory diseases [7]. While p38 MAPK is a direct therapeutic target for inhibitors like losmapimod, FOXO activity is typically modulated indirectly through upstream kinases such as PI3K, AKT, or p38 itself [8, 9]. [1] UniProt: P10000 (DAF-16). [2] UniProt: O43524 (FOXO3). [3] PubMed: 15107404. [4] UniProt: Q16539 (MAPK14). [5] PubMed: 18256283. [6] PubMed: 22560273. [7] PubMed: 21368824. [8] ClinicalTrials.gov: NCT04068454. [9] PubMed: 30301778.
Inhibition of p38 MAPK catalytic activity to reduce pro-inflammatory cytokine production; indirect modulation of FOXO transcriptional activity via inhibition of upstream regulatory kinases (PI3K/AKT/p38) to promote stress resistance or apoptosis.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box O (FOXO) and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways (FOXO/p38 MAPK).